Cerulean Pharma Cmn (CERU) 1.02 $CERU Cerulean Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cerulean Pharma Cmn (CERU) 1.02 $CERU

Cerulean Announces Reduction in Force
BusinessWire - Thu Aug 18, 3:01PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that it is reducing its workforce by approximately 48%, to a total of 23 full-time equivalent employees, under a plan expected to be substantially completed by the end of 2016. This workforce reduction is designed to reduce operating expenses while the company refocuses its clinical strategy for CRLX101. Affected employees are being offered severance and outplacement assistance.
CERU: 1.02 (unch)

Cerulean (CERU) Kidney Cancer Drug Disappoints in Phase II
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:11AM CDT
Cerulean (CERU) announced disappointing top-line results from a phase II, study on CRLX101 for the treatment of patients with advanced RCC.
ANIP: 59.86 (-1.56), CERU: 1.02 (unch), ANIK: 47.89 (-0.05)

Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin(R) Combination in Relapsed Renal Cell Carcinoma
BusinessWire - Wed Aug 17, 3:01PM CDT
--Company to Host Conference Call Today at 4:30 pm EDT
CERU: 1.02 (unch)

Cerulean Reports Second Quarter 2016 Corporate Highlights and Financial Results
BusinessWire - Thu Aug 04, 3:05PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities for the quarter ended June 30, 2016.
CERU: 1.02 (unch)

Cerulean to Host Second Quarter 2016 Conference Call on August 4
BusinessWire - Thu Jul 28, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the second quarter 2016 on August 4.
CERU: 1.02 (unch)

Cerulean Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors
BusinessWire - Thu Jun 23, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in the Phase 2a stage of an ongoing Phase 1/2a clinical trial of CRLX301 in patients with advanced solid tumors.
CERU: 1.02 (unch)

Cerulean Announces Publication in Cancer Research
BusinessWire - Wed Jun 22, 8:20AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of preclinical proof of concept data for its lead compound, CRLX101, in the journal Cancer Research. The publication highlights that CRLX101 demonstrated strong antitumor activity, as monotherapy and in combination with Avastin(R) (bevacizumab), leading to complete tumor regression, reduced metastasis, and extended survival of mice with metastatic disease. These preclinical results were derived from mouse models of orthotropic primary triple-negative breast tumor xenografts, including a patient-derived xenograft and a model of post-surgical, advanced metastatic breast cancer. The article was published online.
CERU: 1.02 (unch)

Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Susan L. Kelley, M.D. to the Company's Board of Directors.
IMDZ: 7.07 (-0.04), CERU: 1.02 (unch)

Cerulean Announces Manuscript Published in Annals of Oncology
BusinessWire - Thu Jun 09, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the manuscript of clinical data for its lead compound, CRLX101, in the journal Annals of Oncology. The manuscript highlights results from an open-label, single arm Phase 1b/2 investigator-sponsored trial (IST) of CRLX101 in combination with Avastin(R) (bevacizumab) in patients with metastatic renal cell carcinoma (RCC). The trial achieved its primary endpoint of establishing a recommended Phase 2 dose and showed preliminary anti-tumor activity. The article is available online. Results from the trial also were presented at the 2015 American Society of Clinical Oncology annual meeting on June 1, 2015 and at the 2015 International Kidney Cancer Symposium on November 4, 2015.
CERU: 1.02 (unch)

Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference
BusinessWire - Thu May 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company will present in an oral session Phase 1b results of an ongoing clinical trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer at the Gynecologic Oncology 2016 Conference being held May 19-21 in San Antonio, Texas. This trial is being conducted by Cerulean in collaboration with the GOG Foundation, Inc.
CERU: 1.02 (unch)

Cerulean to Present at the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:12PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced a scheduled poster presentation on CRLX301 at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, at McCormick Place in Chicago.
CERU: 1.02 (unch)

Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA(TM)
BusinessWire - Tue May 10, 6:30AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA(TM) (olaparib) in patients with advanced solid tumors. This trial is being conducted by the National Cancer Institute (NCI), in collaboration with AstraZeneca and Cerulean. It is under the direction of NCI investigators, Anish Thomas, MBBS, M.D., Staff Clinician at the Thoracic and Gastrointestinal Oncology Branch of the Center for Cancer Research at the NCI, and Yves Pommier, M.D., Ph.D., an expert in DNA repair, and Chief of the Developmental Therapeutics Branch at the NCI.
CERU: 1.02 (unch)

Cerulean reports 1Q loss
Automated Insights - Mon May 02, 4:31PM CDT
WALTHAM, Mass. (AP) _ Cerulean Pharma Inc. (CERU) on Monday reported a loss of $13.5 million in its first quarter.
CERU: 1.02 (unch)

Cerulean Reports First Quarter 2016 Corporate Highlights and Financial Results
BusinessWire - Mon May 02, 3:06PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended March 31, 2016.
CERU: 1.02 (unch)

Cerulean to Host First Quarter 2016 Conference Call on May 2
BusinessWire - Mon Apr 25, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the first quarter 2016 on May 2.
CERU: 1.02 (unch)

Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer
BusinessWire - Tue Apr 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of clinical data in a late-breaker at the 2016 American Association for Cancer Research (AACR) Annual Meeting. Adrian Senderowicz, M.D., Senior Vice President and Chief Medical Officer of Cerulean will present results from the first 18 patients enrolled in an investigator-sponsored trial.
CERU: 1.02 (unch)

Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 1.02 (unch), VVUS: 1.05 (-0.01), PETX: 8.81 (-0.11), GALE: 0.40 (unch)

Cerulean to Present at 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 12:50 p.m. ET.
CERU: 1.02 (unch)

Cerulean Pharma (CERU) Jumps: Stock Moves 8.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:15AM CDT
Cerulean Pharma Inc (CERU) shares rose almost 9% in the last trading session.
CERU: 1.02 (unch), CALA: 3.08 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Flora Growth Corp Sees 6% Surge in After-Hours Performance

Updated Category News Views 87

A Surge in After-Hours Trading for Flora Growth Corp Flora Growth Corp. (NASDAQ: FLGC) recently demonstrated significant volatility by surging 5.98% to $10.55 during after-hours trading. This movement came not long after closing at $9.96, which marked an increase of 3.59% earlier that day. Insights from Recent SEC Filing Regulation A Filing In a notable move, Flora Growth...

Continue Reading
Qubs Introduces Qubitunes, A New Interactive Audio Experience

Updated Category News Views 205

Qubs Launches Qubitunes for Creative Play Qubs has unveiled an exciting new product, Qubitunes, which has already won the 'Top Toy' award in the startup category at a prestigious Toy Fair. This innovative toy is set to transform playtime for children by offering a unique platform where they can express their creativity and dive into their own audio storytelling...

Continue Reading
Asyad Group's Expert Transport of Heavy Cryogenic Tank

Updated Category News Views 126

Asyad Group's Successful Transport of Cryogenic Tank Asyad Group has recently completed a remarkable international transport operation, successfully moving a 115 metric ton pressurized cryogenic tank from Northern India to a major destination in Saudi Arabia. This endeavor highlights the Group's expertise in cross-border logistics. A Journey of Precision The transport...

Continue Reading
Famous Toastery Launches Holiday Fundraising Efforts

Updated Category News Views 134

Famous Toastery's Compassionate Campaign for Local Communities The Famous Toastery, known for its delightful breakfast and brunch offerings, is stepping up this holiday season with a noble initiative aimed at fighting hunger. This renowned franchise is collaborating with Feeding the Carolinas, encouraging guests to make donations that will significantly impact individuals...

Continue Reading
Jiayin Group's Upcoming Earnings Call Set for November 25, 2025

Updated Category News Views 190

Jiayin Group Inc. Announces Q3 2025 Financial Results Release Jiayin Group Inc. (NASDAQ: JFIN), a prominent fintech platform in China, has shared significant news that it will unveil its unaudited financial outcomes for the third quarter of 2025. This crucial announcement is set to occur before the U.S. markets open on November 25, 2025. The anticipation surrounding these...

Continue Reading